Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral everolimus after bare-metal coronary stenting for prevention of 6-month MACE
2005-002992-34Phase 3Terminated
- Sponsor
- Deutsches Herzzentrum der Charité
- Start
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronary arteriosclerosis comparing Everolimus with Placebo (2 arms). Primary endpoint: Major adverse cardiac events within 6 months. Started Mar 2006; status: terminated.
02
Drugs
everolimus
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on 2005-002992-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002992-34.